AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The ...

Lentiviral vectors (LVVs ... has its own peculiarities and associated complexity when compared with other vector types, especially because of the intrinsic characteristics of the vectors ...

There was a dose-dependent, transient increase in serum ALT concentrations using the lentiviral vector not encoding accessory proteins (Fig. 3). In addition, the 8–10×10 8 TU dose of vector was ...

A recent study on T cell gene therapy trials shows that while secondary malignancies occur in a small percentage of patients, ...

Oxford Biomedica plc (OTCMKTS:OXBDF – Get Free Report) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 78,300 shares, an increase of 131.0% ...

AstraZeneca to acquire EsoBiotec to advance cell therapy ambition Acquisition includes world-leading in vivo delivery platform with potential to transform cell therapy AstraZeneca has ...

The gene is carried inside a lentiviral vector, and the medication is administered via inhalation. Lentiviruses work well for gene therapy because they come equipped with the tools needed to ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...